An important aspect of testicular cancer survivorship and QoL that is not always discussed…Excited to share our latest article published in @plosone: journals.plos.org/plosone/articl… Mike Hsieh Darshan Patel, MD DrBagrodia Jim Hotaling, M.D. Joshua Horns UCSD Urology University of Utah Urology

With a median FU up of ~5 yrs adjuvant pembro= 38% reduction in risk of death. The benefit is across subgroups (T stage etc). Subsequent therapy in 80% is relapses. The 1st +ve OS adjuvant PD1 study, making adjuvant pembro more attractive. #GU24 Toni Choueiri, MD

The 340B Drug Pricing Program and oral specialty drugs for advanced prostate cancer. | Journal of Clinical Oncology ascopubs.org/doi/abs/10.120…

HAPPY MATCH DAY, INDEED! Welcome Brian, Ashley, Bradley, and Lulu! 🤩

And cost-effective!

🚨 High-Yield Urology 2024 is Now Available! 👉 13 new/updated guideline summaries 👉 17 new RCT summaries 👉 25 new testing pearls 👉 new and updated tables throughout @uro_res @uroresidency @urologylist @_backtableuro Amer. Urol. Assn. ABU highyieldurology.com

Today, the American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released the 2024 clinical practice guideline on salvage therapy for prostate cancer. View Thread below 👇

Introducing the future of urology leadership! 🌟 Meet our dynamic team of Early Career Editors shaping the next wave of innovation in The Journal of Urology. Bogdana Schmidt MD, MPH Dan Joyce Benjamin Dropkin Anne Dudley, MD George Koch

Comparing the cost-effectiveness of surgery, radiation, and chemo for seminoma. Daniel Joyce, MD joins Ruchika Talwar Vanderbilt Urology to discuss his journey into cost-effectiveness studies, particularly in #TesticularCancer. #WatchNow on UroToday > bit.ly/430EobN

Enfortumab + Pembro outperforms platinum chemotherapy in advanced UC with a doubling of PFS and a halving of the risk of death @nejm. G3/4 AEs of 56% for EVP vs 70% for chemo & CR=29%. Editorial by @gniegisch ‘EVP is the new standard against which future trials must be compared’

Long-term QOL of #GCT patients according to adj treatment pubmed.ncbi.nlm.nih.gov/38658465/ Crucial data informing impact of RPLND, chemo, XRT in CSI and >CSI GCT patients. Surveillance preferred option, but this can guide discussion! Sia Daneshmand, M.D. Scott Eggener Phillip Pierorazio nirm

Don't miss Spyros Basourakos at #AUA24 tomorrow at 9:30am, for poster session on "Contemporary Analysis of Oncological Outcomes of Radical Nephrectomy with Venous Thrombectomy for #RenalCellCarcinoma"

📺 Catch Dan Joyce's (Vanderbilt University Medical Center) discussion with Sarah P. Psutka MD MS (Fred Hutchinson Cancer Center) at #AUA24 on updates in #KidneyCancer research and how the treatment paradigm is changing as a result of #KEYNOTE564. 🎥 Watch Now: buff.ly/4aavQRy

Comparing the cost-effectiveness of surgery, radiation, and chemo for seminoma. Daniel Joyce, MD joins Ruchika Talwar Vanderbilt Urology to discuss his journey into cost-effectiveness studies, particularly in #TesticularCancer. #WatchNow on UroToday > bit.ly/430EobN

KIM1 data from IM010 (adjuvant atezo vs placebo) in RCC shows baseline levels are prognostic & predictive. An ⬆️ predicts relapse & atezo ⬇️ levels. KIM1 is linked with nephrotoxicity & immunity. ASSURE & CM901 data support these result. Looks like we have a RCC biomarker #ASCO24

In this most recent month's Amer. Urol. Assn. news special issue on #AUAAdvocacy, I had the chance to author a piece with Kevin Wymer Vidit Sharma and Dan Joyce on implementing cost-effectiveness into clinical practice guidelines to lower patient cost of care... (1/2)

Really impactful work from YUO Michigan Urology U-M IHPI co-fellow Arnav Srivastava!

🚨 LITESPARK-005 NEJM 🌎🌍🌏 RCT, 746 pts w/ advanced or mRCC s/p immuno and antiangioenic Tx ➡️ Belzutifan (HIF-2a inhibitor) vs. everolimus ➡️ PFS at 18 mos (24 vs. 8%, p <.01) favored Belzutifan ➡️ med OS (21 vs. 18 mos p=0.2) similar btw groups nejm.org/doi/full/10.10…

Advanced #ProstateCancer: Understanding out-of-pocket medication costs. Daniel Joyce, MD, MS joins Ruchika Talwar Vanderbilt Urology in this important discussion on the financial impact of advanced #PCa treatments on patients. #WatchNow on UroToday > bit.ly/3ADoASf

The Vanderbilt University Ingram Cancer Center Genitourinary team is expanding. We are seeking a GU medical oncology clinical investigator to join our innovative team. Please message me or Brian Rini, MD to inquire further. We will also be at #ESMO24